KRAS and breast cancer: Regarding the other actionable genetic alterations (AGAs) of BC with clinical evidence level equal to 1−212,13, FGFR2 and KRAS amplifications tended to more frequent and PIK3CA amplification more frequent in the Basal subtype (Table S3).